Evidence map›Paper›PMID 27895008›Full record

ArticleAntimicrobial agents and chemotherapy2017

De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.

Jees Sebastian, Sharmada Swaminath, Rashmi Ravindran Nair, Kishor Jakkala, Atul Pradhan, Parthasarathi Ajitkumar

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Article
  3. Identification of a novel gene inAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Netupitant Exhibits Potent Activity onACS infectious diseases · 2025
    Article
  8. Antibiotic-recalcitrant Salmonella during infection.Nature reviews. Microbiology · 2025
    Review
  9. Article
  10. Article
  11. Altered serine metabolism promotes drug tolerance inAntimicrobial agents and chemotherapy · 2024
    Article
  12. Article
  13. Review
  14. Fate ofFrontiers in microbiology · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Microbiology spectrum · 2023
    Article
  19. Eradication of Drug-TolerantMicroorganisms · 2023
    Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jees SebastianDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Sharmada SwaminathDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Rashmi Ravindran NairDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Kishor JakkalaDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Atul PradhanDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Parthasarathi AjitkumarDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India ajitkpartha@gmail.com.
Indian Institute of Science Bangalore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial persisters are a subpopulation of cells that can tolerate lethal concentrations of antibiotics. However, the possibility of the emergence of genetically resistant mutants from antibiotic persister cell populations, upon continued exposure to lethal concentrations of antibiotics, remained unexplored. In the present study, we found that Mycobacterium tuberculosis cells exposed continuously to lethal concentrations of rifampin (RIF) or moxifloxacin (MXF) for prolonged durations showed killing, RIF/MXF persistence, and regrowth phases. RIF-resistant or MXF-resistant mutants carrying clinically relevant mutations in the rpoB or gyrA gene, respectively, were found to emerge at high frequency from the RIF persistence phase population. A Luria-Delbruck fluctuation experiment using RIF-exposed M. tuberculosis cells showed that the rpoB mutants were not preexistent in the population but were formed de novo from the RIF persistence phase population. The RIF persistence phase M. tuberculosis cells carried elevated levels of hydroxyl radical that inflicted extensive genome-wide mutations, generating RIF-resistant mutants. Consistent with the elevated levels of hydroxyl radical-mediated genome-wide random mutagenesis, MXF-resistant M. tuberculosis gyrA de novo mutants could be selected from the RIF persistence phase cells. Thus, unlike previous studies, which showed emergence of genetically resistant mutants upon exposure of bacteria for short durations to sublethal concentrations of antibiotics, our study demonstrates that continuous prolonged exposure of M. tuberculosis cells to lethal concentrations of an antibiotic generates antibiotic persistence phase cells that form a reservoir for the generation of genetically resistant mutants to the same antibiotic or another antibiotic. These findings may have clinical significance in the emergence of drug-resistant tubercle bacilli.

Indexed as

Antitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesDNA GyraseDose-Response Relationship, DrugDrug Resistance, BacterialFluoroquinolonesGenome, BacterialHydroxyl RadicalMoxifloxacinMutationMycobacterium tuberculosisOxidative StressRifampinAntitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesDNA GyraseFluoroquinolonesHydroxyl RadicalMoxifloxacinRifampinrpoB protein, Mycobacterium tuberculosisantibiotic resistancehydroxyl radicalmoxifloxacinMycobacterium tuberculosispersistence phase cellsrifampicin

Identifiers

PMID27895008
PMCPMC5278719
OpenAlexW2558769558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.